HPV-Negative Head & Neck Cancer: Hope in Immunotherapy

A groundbreaking Phase 2 clinical trial conducted by researchers at the University of Chicago Medicine Comprehensive Cancer Center has shown promising results in treating advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). The study, published in JAMA Oncology, demonstrated that combining immunotherapy (nivolumab) with chemotherapy before radiation or surgery led to tumor shrinkage in more than half of the patients.

This innovative treatment strategy could improve survival rates while reducing the harsh side effects associated with traditional treatments.

Challenges in Treating HPV-Negative HNSCC

Unlike HPV-positive head and neck cancer, HPV-negative HNSCC is often linked to heavy smoking and alcohol use and is more difficult to treat. Patients usually experience:

• Later-stage diagnoses (Stage 3 or 4) due to mild early symptoms
• Limited survival benefits from current treatments (surgery or chemo-radiation)
• Severe side effects, including speech and swallowing difficulties

There is an urgent need for new treatment strategies to improve outcomes and quality of life for these patients.

Immunotherapy as a Game-Changer

Researchers tested a neoadjuvant (pre-treatment) approach, using a combination of:

• Nivolumab (an immune checkpoint inhibitor)
• Three cycles of chemotherapy
• Followed by response-based chemo-radiation

Key Findings:

• 53% of patients saw their tumors shrink by at least 50%
• Patients with higher PD-L1 expression responded better, suggesting it could be used as a biomarker for treatment selection
• Patients who responded well to the pre-treatment received lower-intensity radiation, leading to fewer side effects

“This study is the first to explore neoadjuvant chemo-immunotherapy with response-based de-escalation in non-surgical HPV-negative HNSCC patients. The results pave the way for new treatment paradigms that enhance both survival and quality of life.” – Dr. Ari Rosenberg, Lead Investigator

Why This Study Matters

• Potential for personalized treatment based on PD-L1 biomarker testing
• Better survival outcomes with fewer long-term side effects
• Possibility of avoiding surgery in some cases

This breakthrough approach could redefine standard care for advanced head and neck cancer patients, offering hope for a better future.

More Information: Rosenberg, A. J., et al. (2025). Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer. JAMA Oncology. doi.org/10.1001/jamaoncol.2025.0081.